亚洲社会药学

本期目录

2014年, 第9卷, 第2期　刊出日期：2014-06-20 上一期    下一期

论文

Select

Analysis of Influential Factors on the Efficacy of Itraconazole Injection forTreating Fungal Infections in Hematologic Malignancies Patients DONG Wei-hua;;HUANG Tai-kang;;DONG Ya-lin;ZHOU Yang 2014 (2):  47-50.  doi: 摘要 ( 496 )   Objective To analyze the influential factors on the efficacy of itraconazole injection in the treatment of fungal infections for hematologic malignancies patients. Methods 85 hematologic malignancy patients with fungal infections were selected to treat with itraconazole injection. Multiple logistic regression was used to analyze 27 factors that probably affect the efficacy of itraconazole injection, these factors including four aspects: basic situation of the patients, use of itraconazole injection, combined drugs use, and laboratory indicators before and after treatment. Results and Conclusion Four factors such as the patient’s gender, the combination of fluconazole, macrolides, and carbamazepine were eventually conducted into the regression equation and we found the factors that reduce the efficacy of itraconazole injection were the combination use of fluconazole and carbamazepine. 相关文章 | 计量指标

Select

Analysis of China’s Health Care Resource Allocation KONG Ling-da;LIU Ya-dan;WU Zhi-ang 2014 (2):  51-55.  doi: 摘要 ( 578 )   Objective To provide references for rational allocation of China’s health care resources. Methods Descriptive analysis and cluster statistics were conduced to analyze China’s health care resource allocation. Results and Conclusion Health care resource allocation is unreasonable to some degree and countermeasures are raised. 相关文章 | 计量指标

Select

Chinese Herbal Medicine Exports: Existing Problems and Reflections ZHANG Zhi-dong;SUN Li-hua 2014 (2):  56-59.  doi: 摘要 ( 544 )   Objective To discuss the problems and reasons of the export situation of Chinese herbal medicines, and to provide suggestions for policy making. Methods Literature review was conducted to discuss the problems, such as resources pressure that Chinese herbal medicine export has brought about, technical trade barriers, and the low industry concentration of the export enterprises, etc. Results and Conclusion With the development of Chinese herbal medicine exports, China should perfect policies and regulations to protect the wild resources, formulate China’s export standards to deal with technical trade barriers, enhance the access threshold of export enterprises so as to enhance the competitiveness of the industry. 相关文章 | 计量指标

Select

Biosimilars: Current Status and Countermeasures LI Yan-ru;TIAN Li-juan 2014 (2):  60-63.  doi: 摘要 ( 500 )   Objective To study the current status of biosimilars, and to explore strategies for the healthy development of biosimilars in China. Methods Literature review was conducted to summarize the status of biosimilars both at home and abroad. Results and Conclusion The development of biosimilars in China is not yet mature compared with the advanced countries. Support from both companies and the state is needed to promote the development of biosimilars in China. 相关文章 | 计量指标

Select

China’s Marine Biopharmaceutical Industry:Existing Problems and Countermeasures ZHANG Li-jun;HUANG Tai-kang; 2014 (2):  64-67.  doi: 摘要 ( 551 )   Objective To explore the problems faced by marine biopharmaceutical industry in China and to put forward countermeasures. Methods Literature review was conducted and the problems faced by China’s marine biopharmaceutical industry were analyzed from the perspectives of scale, technology, financing, management and distribution. Accordingly, countermeasures were raised. Results and Conclusion Marine biopharmaceutical industry is the strategic emerging industry. The existing problems in the development of marine biopharmaceutical industry in china will be solved through strengthening overall coordination, promoting management innovation, consolidating science and technology, fostering industrial cluster and increasing capital investment. 相关文章 | 计量指标

Select

The Comparison of IND Review Mechanismbetween China and the United States JIANG Chun-fei;YANG Yue 2014 (2):  68-72.  doi: 摘要 ( 503 )   Objective To study IND review mechanism between China and the United States, and to comment the advantages of review mechanism by FDA. Methods Literature review was conducted and official websites of drug regulatory authorities at home and abroad were searched to gain relevant information. Results and Conclusion IND registration management legal system in China is less perfect than that in the United States. IND review organization and procedures need to be further optimized. 相关文章 | 计量指标

Select

Research of the Classification of Drug Risks YAN Quan;SHAO Rong 2014 (2):  73-78.  doi: 摘要 ( 547 )   Objective To classify drug risks according to the life cycle of drugs. Methods Case analysis was used to discuss the causes of drug injury events in the past decade, and to classify the drug risks. Results and Conclusion Drug risks can exist in four processes: drug research and development, manufacturing, management and drug use, which can be further detailed into 20 indicators. The classification of drug risks is scientific and rational, so it can help to allocate drug supervision resources rationally. 相关文章 | 计量指标

Select

Marketing Channel Selectionsfor Different Biological Reagent Enterprises in China BAI Jian;;MIAO Lan-ying;LIN Da-yong;WANG Hai-bo;LI Ye 2014 (2):  79-82.  doi: 摘要 ( 591 )   Objective To probe into marketing channel selections for different biological reagent enterprises. Methods Influential factors on marketing channel selections for different biological reagent enterprises were discussed, and matrix model of product technical barriers-enterprise strength was built to study the causes and feasibilities of marketing channel selections for different biological reagent enterprises. Results and Conclusion It is suggested that the state-owned enterprises, foreign - invested enterprises, joint ventures should adopt directly- managed marketing channel, medium and small-sized enterprises adopt the agent marketing channel, patented the product- oriented enterprises adopt both the district agent marketing channel and the directly- managed marketing channel, and enterprises with low threshold technology adopt the multi-agent marketing channel. 相关文章 | 计量指标

Select

Countermeasures to Reduce Economic Burden of the Schizophrenia in China DU Li-zhe;SUN Li-hua 2014 (2):  83-86.  doi: 摘要 ( 561 )   Objective To provide a theoretical reference and decision support for health care policy makers so as to reduce economic burden of the Schizophrenia. Methods Retrospective study was conducted to analyze measures to reduce the economic burden of the schizophrenia, and suggestions were raised based on learning experiences from other countries and practices in China. Results and Conclusion Comprehensive intervention of hospitals and communities as well as the policy system of basic health care insurance and social assistance can significantly reduce the economic burden of the schizophrenia. 相关文章 | 计量指标

Select

Patent Status of Antidepressants: Duloxetine LI Jun-li;WEN Qi;YU Pei-ming 2014 (2):  87-91.  doi: 摘要 ( 519 )   Objective To study the patent status of duloxetine and to provide references for the strategic development of pharmaceutical companies in China. Methods Patent status of duloxetine in China were analyzed by quantitative and qualitative methods of research. Results and Conclusion Generic manufacturers can produce duloxetine legally when the administrative protection ends on December 11, 2013. But crystal and process patents should be paid attention to avoid infringement. The generic manufacturers can analyze the patents of synthesis process and pharmaceutical formulations, to obtain the best processing route to reduce production cost or to apply for patents on their own. There is still great potential for pharmaceutical companies in China to make new breakthroughs by absorbing technology in previous patents. 相关文章 | 计量指标

Select

Study on the Pharmaceutical E-commerce B to C Modelfrom Perspective of Transaction Costs ZHANG Lei;XING Hua;WU Yang 2014 (2):  92-95.  doi: 摘要 ( 535 )   Objective To probe into the reasons why pharmaceutical E-commerce develops slowly and to promote the E-commerce applications to pharmaceutical retail industry. Methods Pharmaceutical e-commerce and traditional retail models were compared, and some suggestions were raised from the perspective of transaction costs. Results and Conclusion At present, transaction costs of the emerging pharmaceutical E-commerce B to C model have not been reduced much compared with the traditional retail model, that is, E-commerce B to C model has not gained a significant advantage. Therefore, government, enterprises and other parties should cooperate to cut down the transaction costs of drugs via the Internet so as to promote the E-commerce applications to the pharmaceutical retail industry. 相关文章 | 计量指标